Meridian Bioscience Inc (VIVO) 19.60 $VIVO
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Meridian Bioscience to launch illumigene Mycoplasma and Pertussis diagnostic tests in Canada upon approval
M2 - Thu May 29, 5:34AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) reported on Wednesday the receipt of Health Canada's medical device license approval to market two additional assays for use on their illumigene molecular diagnostic platform.
Meridian Bioscience Receives Canadian Licenses for illumigene(R) Mycoplasma and illumigene(R) Pertussis
Business Wire - Wed May 28, 10:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene(R) molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
The Zacks Analyst Blog Highlights:Boeing, Embraer, Meridian Bioscience, Cardica and Eagle Pharmaceuticals
PR Newswire - Tue May 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Boeing Co. (NYSE:BA-Free Report), Embraer S.A. (NYSE:ERJ-Free Report), Meridian Bioscience, Inc. (Nasdaq:VIVO-Free Report), Cardica Inc. (Nasdaq:CRDC-Free Report) andEagle Pharmaceuticals Inc. (Nasdaq:EGRX-Free Report).
Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Forecast to 2018
M2 - Mon May 26, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p53nrx/isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Forecast to 2018" report to their offering. The isothermal nucleic acid amplification technology (INAAT) market is poised to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period. Despite the dominance of polymerase chain reaction (PCR) technology, INAAT is expected to seize a considerable market space in the global market since it enhances the quality of point-of-care testing using miniature DNA diagnostics. Major driving factors of the global market includes increasing prevalence of infectious disease and cancer, promise for less expensive and better throughput in gene amplification using INAAT, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA). However, inadequate automation and portability, and high dominance of PCR technology restrict the adoption of isothermal amplification technology globally. Reagent segment held the maximum share of 70% of the global market in 2013; the segment is expected to grow at 14.7% CAGR due to increasing consumption of reagents in the detection of chronic diseases and genetic disorders. Future scope of market development lies in less expensive and portable POCT device as well as real time Chip based Nucleic Acid Testing (NAT) for SNP genotyping and cancer. Currently, difficulties in developing lab-on-chip due to lack of multidisciplinary approach, and high entry barrier in PCR dominated emerging nations restrict the market momentum in the developing countries. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Technology Landscape Analysis 4 Technology Investment Potential 5 Market Landscape Analysis 6 Product Market 7 Applications Market 8 End-User Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Alere - Becton, Dickinson and Company (Bd) - Biohelix - Biomerieux - Eiken Chemical Co., Ltd. - Hologic Gen-Probe - Lucigen - Meridian Bioscience, Inc. - New England Biolabs - Novartis Diagnostics - Nugen - Qiagen - Ustar Biotechnologies For more information visit http://www.researchandmarkets.com/research/p53nrx/isothermal
Meridian Bioscience Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 12:00PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) saw six downward estimate revisions over the last one month with no upward revision.
Is Now the Right Time for This Small-Cap Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Thu May 22, 2:42PM CDT
When it comes to investing for the long term, one of your best bets is to consider stocks that pay a regular dividend. By that same token, dividend stocks tend to command a premium price since investors specifically seek them out. Meridian...
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Meridian Bioscience to launch illumigene Mycoplasma and Pertussis diagnostic tests in Canada upon approval
M2 - Thu May 29, 5:34AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) reported on Wednesday the receipt of Health Canada's medical device license approval to market two additional assays for use on their illumigene molecular diagnostic platform.
Meridian Bioscience Receives Canadian Licenses for illumigene(R) Mycoplasma and illumigene(R) Pertussis
Business Wire - Wed May 28, 10:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene(R) molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
The Zacks Analyst Blog Highlights:Boeing, Embraer, Meridian Bioscience, Cardica and Eagle Pharmaceuticals
PR Newswire - Tue May 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Boeing Co. (NYSE:BA-Free Report), Embraer S.A. (NYSE:ERJ-Free Report), Meridian Bioscience, Inc. (Nasdaq:VIVO-Free Report), Cardica Inc. (Nasdaq:CRDC-Free Report) andEagle Pharmaceuticals Inc. (Nasdaq:EGRX-Free Report).
Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Forecast to 2018
M2 - Mon May 26, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p53nrx/isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Forecast to 2018" report to their offering. The isothermal nucleic acid amplification technology (INAAT) market is poised to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period. Despite the dominance of polymerase chain reaction (PCR) technology, INAAT is expected to seize a considerable market space in the global market since it enhances the quality of point-of-care testing using miniature DNA diagnostics. Major driving factors of the global market includes increasing prevalence of infectious disease and cancer, promise for less expensive and better throughput in gene amplification using INAAT, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA). However, inadequate automation and portability, and high dominance of PCR technology restrict the adoption of isothermal amplification technology globally. Reagent segment held the maximum share of 70% of the global market in 2013; the segment is expected to grow at 14.7% CAGR due to increasing consumption of reagents in the detection of chronic diseases and genetic disorders. Future scope of market development lies in less expensive and portable POCT device as well as real time Chip based Nucleic Acid Testing (NAT) for SNP genotyping and cancer. Currently, difficulties in developing lab-on-chip due to lack of multidisciplinary approach, and high entry barrier in PCR dominated emerging nations restrict the market momentum in the developing countries. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Technology Landscape Analysis 4 Technology Investment Potential 5 Market Landscape Analysis 6 Product Market 7 Applications Market 8 End-User Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Alere - Becton, Dickinson and Company (Bd) - Biohelix - Biomerieux - Eiken Chemical Co., Ltd. - Hologic Gen-Probe - Lucigen - Meridian Bioscience, Inc. - New England Biolabs - Novartis Diagnostics - Nugen - Qiagen - Ustar Biotechnologies For more information visit http://www.researchandmarkets.com/research/p53nrx/isothermal
Meridian Bioscience Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 12:00PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) saw six downward estimate revisions over the last one month with no upward revision.
Is Now the Right Time for This Small-Cap Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Thu May 22, 2:42PM CDT
When it comes to investing for the long term, one of your best bets is to consider stocks that pay a regular dividend. By that same token, dividend stocks tend to command a premium price since investors specifically seek them out. Meridian...
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
